Julie Stephenson Joins BioSig as Senior Director of Clinical Affairs
July 24 2019 - 7:52AM
BioSig Technologies, Inc. (NASDAQ: BSGM), a medical
device company developing a proprietary biomedical signal
processing technology platform designed to address an unmet need
for the electrophysiology (EP) marketplace, today announced that
Ms. Julie Stephenson, BSN, MBA joined the Company as Senior
Director of Clinical Affairs.
Mrs. Stephenson brings to BioSig over 20 years of cardiac device
technology experience having served in various clinical, sales, and
marketing roles at Medtronic, Boston Scientific, and Guidant
Corporation. Most recently, Mrs. Stephenson served as Director of
Medical Education at Medtronic, a role in which she developed and
delivered over 10 national peer-to-peer education programs annually
and was responsible for numerous other supplemental educational
resources for EP fellows. This work included collaboration with
internationally recognized physician leaders. Other highlights of
Mrs. Stephenson’s career with Medtronic included supervising the
contracting and honoraria processes, serving as the Medical
Education Liaison to Latin America, and participating in the Global
Innovation Fellowship Program.
Earlier in her career, Mrs. Stephenson was the Regional Sales
Manager with Boston Scientific in Central New Jersey for three
years. During this time Mrs. Stephenson was responsible for driving
meaningful sales revenues. Prior to this, she served as a Sales
Representative and Field Clinical Representative with Guidant
Corporation for 7 years.
A critical care nurse by training, Mrs. Stephenson holds a BSN
degree from Northwestern State University and MBA from The Darden
School of Business at University of Virginia. Mrs. Stephenson
received numerous awards, including the President’s Club Award,
Regional Sales Manager of the Year (New York Area), a Patent Award,
and the Faculty Award.
“Julie was recommended to us by one of the most recognized key
opinion leaders in the global medical innovation space,” stated
Kenneth L. Londoner, Founder, Chairman and CEO of BioSig
Technologies, Inc. “Julie brings to us a wealth of experience in
medical affairs, ranging from effective physician engagement to
education to successful sales, and we are confident that she will
be an invaluable addition to our clinical team. We are proud of our
continued abilities to attract top talent, and every member of our
growing team is working tirelessly on behalf of our
shareholders.”
BioSig has been actively adding to its operations, having
recently announced several new additions to the management team and
the Board of Directors. BioSig recently announced that it has been
added to the Russell 3000 Index and was allowed 33 patent claims
covering its PURE EP™ System. In the first half of 2019 BioSig
successfully conducted first patient cases using its PURE EP™
System at the Texas Cardiac Arrhythmia Institute in Austin, TX,
Greenville Memorial Hospital in Greenville, SC and Indiana
University School of Medicine. These initial experiences suggested
improved cardiac signal detection and fidelity.
About BioSig TechnologiesBioSig Technologies is
a medical technology company developing a proprietary biomedical
signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosig.com). Led by a
proven management team and a veteran Board of Directors, BioSig
Technologies is preparing to commercialize its PURE EP™ System. The
technology has been developed to address an unmet need in a large
and growing market.The Company’s first product, PURE EP™ System is
a computerized system intended for acquiring, digitizing,
amplifying, filtering, measuring and calculating, displaying,
recording and storing of electrocardiographic and intracardiac
signals for patients undergoing electrophysiology (EP) procedures
in an EP laboratory. The system is indicated for use under the
supervision of licensed healthcare practitioners who are
responsible for interpreting the data. This novel cardiac signal
acquisition and display system is engineered to assist
electrophysiologists in clinical decision-making during
electrophysiology procedures in patients with abnormal heart rates
and rhythms. BioSig’s ultimate goal is to deliver technology to
improve upon catheter ablation treatments for the prevalent and
potentially deadly arrhythmias, Atrial Fibrillation and Ventricular
Tachycardia. BioSig has partnered with Minnetronix on technology
development and received FDA 510(k) clearance for the PURE EP™
System in August 2018.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (ii) difficulties in
obtaining financing on commercially reasonable terms; (iii) changes
in the size and nature of our competition; (iv) loss of one or more
key executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
54 Wilton Road, 2nd floor
Westport, CT 06880
ndrapeau@biosigtech.com
310-620-9320
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024